BlackRock Amends ANAPTYSBIO Stake, Remains Passive Investor
Ticker: ANAB · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1370053
| Field | Detail |
|---|---|
| Company | Anaptysbio, Inc (ANAB) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, pharmaceuticals
TL;DR
**BlackRock still owns ANAPTYSBIO stock, but they're just holding, not trying to run the show.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating its ownership of ANAPTYSBIO, INC. common stock as of December 31, 2023. This filing is an update to previous disclosures, showing BlackRock's continued significant, but passive, investment in the pharmaceutical company. For investors, this means a major institutional player maintains a stake, which can signal confidence, but the passive nature suggests no immediate plans for influencing company management.
Why It Matters
This filing confirms BlackRock's ongoing, substantial investment in ANAPTYSBIO, INC., providing a degree of institutional validation for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any new risks or significant changes in strategy.
Analyst Insight
An investor should note BlackRock's continued passive stake as a sign of long-term institutional interest, but not as an indicator of imminent strategic changes or activist involvement.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- ANAPTYSBIO, INC. (company) — the issuer whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will continue to hold a significant, passive stake in ANAPTYSBIO, INC. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is BlackRock Inc., a major institutional investment manager.
What is the 'Subject Company' or 'Issuer' of the securities mentioned in this filing?
The 'Subject Company' or 'Issuer' is ANAPTYSBIO, INC., a pharmaceutical preparations company with CIK 0001370053.
What is the 'Title of Class of Securities' that BlackRock Inc. is reporting on?
The 'Title of Class of Securities' is Common Stock of ANAPTYSBIO, INC.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding ANAPTYSBIO, INC (ANAB).